17 research outputs found
Geographic analysis on the occurrence of human and canine leptospirosis in the city of Maringá, state of Paraná, Brazil
Assessment of obstruction length and optimal viewing angle from biplane X-ray angiograms
Prevalence of HCV infection and associated factors among illicit drug users in Breves, State of Pará, northern Brazil
Quality of life and burden in carers for persons with Chronic Obstructive Pulmonary Disease receiving oxygen therapy
Tuberculin skin test and ELISPOT/T. SPOT.TB in children and adolescents with juvenile idiopathic arthritis
The mitochondrial genome of the primary screwworm fly Cochliomyia hominivorax (Diptera : Calliphoridae)
The complete sequence of the mitochondrial genome of the screwworm Cochliomyia hominivorax was determined. This genome is 16 022 bp in size and corresponds to a typical Brachycera mtDNA. A Serine start codon for COI and incomplete termination codons for COII, NADH 5 and NADH 4 genes were described. The nucleotide composition of C. hominivorax mtDNA is 77% AT-rich, reflected in the predominance of AT-rich codons in protein-coding genes. Non-optimal codon usage was commonly observed in C. hominivorax mitochondrial genes. Phylogenetic analysis distributed the Acalypterate species as a monophyletic group and assembled the C. hominivorax (Calyptratae) and the Acalyptratae in a typical Brachycera cluster. The identification of diagnostic restriction sites on the sequenced mitochondrial genome and the correlation with previous RFLP analysis are discussed.9552152
Comparação da força muscular respiratória, qualidade de vida e capacidade funcional entre adolescentes com fibrose cística com diferentes perfis bacteriológicos
Avaliação do crescimento, do controle laboratorial e da corticoterapia em um grupo de pacientes com a forma clássica da deficiência da 21-hidroxilase Evaluation of growth, laboratorial control and corticotherapy in a sample of patients with the classical form of 21-hydroxylase deficiency
OBJETIVO: Avaliar o padrão de crescimento de pacientes com hiperplasia adrenal congênita com a forma clássica da deficiência da 21-hidroxilase (21-OH), em relação ao controle hormonal e ao uso de corticóide no tratamento. MÉTODOS: Análise retrospectiva dos prontuários de 45 pacientes. Como padrão de crescimento, foi utilizado o ganho ou não de altura, avaliando-se a diferença entre o escore Z da estatura na última consulta (para idade óssea) em relação ao escore Z da estatura no início do tratamento (para a idade cronológica). Foram avaliadas todas as concentrações de 17-OH progesterona (17-OHP), androstenediona e renina, sendo considerados bem controlados os pacientes com 50% ou mais das dosagens normais. Em relação ao corticóide, foram analisados o tipo e a dose. RESULTADOS: A idade na última consulta variou de 2,8 a 26,6 anos (12,6+5,8 anos), sendo 31 do sexo feminino, 30 com a forma perdedora de sal; 62% foram considerados bem controlados para 17-OHP, 75% para androstenediona e 78% para renina. A hidrocortisona foi usada por 41 pacientes (20,2+2,6 mg/m²/dia) e, por 40, em associação com a 9a-fludrocortisona. Encontrou-se 14 pacientes com ganho, 20 com manutenção e 11 com perda estatural. Os pacientes perdedores de sal (p=0,01) e os bem controlados (p=0,0005) para 17-OHP e androstenediona apresentaram associação significativa com o ganho de estatura. CONCLUSÕES: Nesta amostra de pacientes com a forma clássica da deficiência da 21-OHD, o melhor crescimento apresentou associação com o bom controle laboratorial da 17-OHP e da androstenediona e com a forma perdedora de sal.<br>OBJECTIVE: To verify the growth pattern of patients with congenital adrenal hyperplasia (CAH) due to classical 21hydroxylase (21-OH) deficiency in relation to hormonal control and use of corticoid during the treatment. METHODS: Retrospective analysis of data from 45 patients. The growth pattern was analyzed according to height gain or not, using the difference between height Z score (for bone age) at the last visit in relation to the height Z score (for chronological age) in the first visit. Concentrations of 17-OH progesterone (17-OHP), androstenedione and rennin were evaluated, and the patients were considered well-controlled when 50% or more of the dosages were normal. Corticoid therapy was analyzed according to type and dose. RESULTS: The age at last visit ranged from 2.8 to 26.6 years (12.6+5.8 years), 31 were females, 30 with salt wasting form; 62% were considered well-controlled for 17-OHP, 75% for androstenedione and 78% for renin. Hidrocortisone was used in 41 patients (20.2+2.6 mg/m²/day) and 40 in association with 9a-fludrocortisone. There were 14 patients with height gain, 20 with maintenance and 11 with loss. Height gain was associated with salt wasting patients (p=0.01) and with patients well-controlled for 17OHP (p=0,0005) and androstenedione (p=0,02). CONCLUSIONS: In this sample of patients with CAH due to classical 21-OH deficiency, better height gain was associated with a good control of 17-OHP and androstenedione and with salt wasting clinical form of the disease